West Pharmaceutical Services Inc (WST) · Oct 29, 2026 · Earnings
Beat — Adjusted EPS $2.66 vs ~$2.20 consensus; revenue $874.5M vs ~$827M consensus
West Pharmaceutical’s Q3 earnings beat consensus by a wide margin, led by HVP components, and the company raised full-year guidance despite West Vantage weakness.
West is shifting its injectable-drug packaging and delivery business toward higher-value components serving biologics, GLP-1 therapies, and regulatory-driven upgrades such as Annex 1; that HVP mix is already the company’s main growth and margin engine. Its prior-quarter outlook had already called for strong HVP-led growth and a full-year guidance increase, so the direction was known; the surprise is the size of the acceleration.
This was a broad operating beat, not just a favorable accounting comparison. Q3 revenue reached $874.5 million versus a published consensus of roughly $827 million, while adjusted EPS was $2.66 versus roughly $2.20. The filing’s own prior-year comparison also shows the underlying improvement: organic sales rose 11.9%, adjusted operating margin expanded to 25.3% from 21.1%, and adjusted EPS rose 35.7%. 〔0〕
| Metric | Q3 2026 | Q3 2025 | Consensus | Prior FY guide |
|---|---|---|---|---|
| Revenue (Financial Statements) | $874.5M (+8.7%) | $804.6M | ~$827M | |
| Adjusted EPS (Non-GAAP reconciliation) | $2.66 (+35.7%) | $1.96 | ~$2.20 | |
| Adjusted operating margin (Segment results) | 25.3% | 21.1% | ||
| FY revenue guidance (Guidance overview) | $3.41B–$3.42B | $3.345B–$3.380B | ||
| FY adjusted EPS guidance (Guidance overview) | $9.38–$9.48 | $8.85–$9.05 |
The core proprietary-products business is materially outperforming the weaker division. Proprietary Products, 83% of quarterly sales, grew 16.6% organically, led by HVP Components up 20.3% organically and HVP Delivery Devices up 26.4% after excluding the SmartDose divestiture. Biologics grew 23.2% organically and Pharma 21.4%, showing that demand is broad across injectable-drug categories rather than dependent on one product. The filing says, “The robust sales performance drove strong operating income margin expansion and EPS growth.”
The mix shift is doing the economic work. HVP Components now represent 53% of total company sales, and the company says HVP conversions, including Annex 1 projects, contributed more than 200 basis points of organic revenue growth. That matters because the proprietary segment’s operating margin reached 31.6%, up 450 basis points year over year, while its gross margin reached 44.4%. This is evidence that West is not merely selling more; it is selling a richer mix at better margins.
West Vantage remains the clear drag, but it was less bad than feared. The segment declined 6.6% organically as the planned loss of a continuous-glucose-monitoring customer flowed through, and its operating margin fell to 10.6% from 14.2%. Still, the filing says results were “slightly better than expected,” while margins improved sequentially as the business recovered from the second-quarter cyber incident. That limits the negative read: the weakness is real, but it did not derail the quarter or the guidance raise. 〔1〕
The guidance increase is the most important change to the business story. Management raised full-year revenue guidance from $3.345–$3.380 billion to $3.410–$3.420 billion and adjusted EPS guidance from $8.85–$9.05 to $9.38–$9.48. The new range implies the company expects the Q3 strength—especially HVP demand and margin expansion—to persist through year-end, rather than treating the quarter as a one-off. The filing also confirms that no additional SmartDose 3.5mL sales are expected for the rest of 2026, so the raised outlook is not being propped up by that divested product.
Cash deployment is aggressive but not the central signal. West repurchased $685.3 million of stock through nine months, while free cash flow was $278.4 million versus $293.9 million a year earlier. The gap reflects working-capital pressure and heavy shareholder returns, but the earnings beat and higher outlook are driven by operating performance rather than buybacks alone.
Bottom line: West’s HVP-led growth is running well ahead of the prior plan, converting strong biologics and GLP-1 demand into higher margins and a meaningful guidance raise. West Vantage is still a weak spot, but it is too small to offset the stronger proprietary-products engine this quarter.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!